Article Data

  • Views 685
  • Dowloads 148

Original Research

Open Access

Simultaneous integrated intensity modulated radiotherapy boost for gynecological cancer when brachytherapy is not an option

  • Eda Kucuktulu1,*,
  • Ahmet Fatih Yurekli2

1SBU Trabzon Kanuni Training and Research Hospital. Dept of Radiation Oncology. Trabzon, Turkey

2Gulhane Training and Research Hospital. Department of Radiation Oncology Ankara, Turkey

DOI: 10.31083/j.ejgo.2020.05.5453 Vol.41,Issue 5,October 2020 pp.720-725

Submitted: 26 December 2019 Accepted: 23 July 2020

Published: 15 October 2020

*Corresponding Author(s): Eda Kucuktulu E-mail: ekucuktulu@yahoo.com

Abstract

Objective: Brachytherapy (BT) lowers the risk of recurrence and improves the survival rate when used after external beam radiotherapy (EBRT) in cervical cancers. In endometrial cancers vaginal cuff BT lowers the risk of vaginal recurrence. New treatment methods have been investigated since BT is not an option for some patients mainly due to difficulties in the placement of BT applicators. Simultaneous integrated boost (SIB) has recently been investigated as an alternative modality in patients when BT is not suitable after EBRT. Materials and Methods: Five patients with cervical cancer and four patients with endometrial cancer were treated with SIB IMRT. In the five cervical cancer patients SIB treatment volumes were given a 74 Gy dose in 2,54 Gy fractions and common iliac and presacral lymphatic lymph node volumes were given 50,4 Gy in 1,74 Gy fractions. In the four patients with endometrial cancer the vagina and paravaginal-parametrial regions received a dose of 60 Gy in 2,3 Gy fractions using a 10 mm margin while a dose of 45 Gy in 1,73 fractions was administered to common iliac, external-internal iliac and obturator lymph nodes. Results: The five patients with the diagnosis of inoperable cervical cancer remained in complete remission (CR) through a median follow-up of 45 months (18-78 months) with a local control (LC) rate of 100%. Acute side effects were seen in 2 patients with cervical cancer and in 2 patients with endometrial cancer. Late side effects were observed in one patient in each of the cervical and endometrial cancer groups. Discussion: SIB-IMRT is an alternative treatment option for patients with cervical or endometrial cancer. Although this pilot study describes a limited number of patients it does suggest long term favorable results can be obtained with this method.


Keywords

Cervical cancer; Endometrial cancer; SIB; IMRT.


Cite and Share

Eda Kucuktulu,Ahmet Fatih Yurekli. Simultaneous integrated intensity modulated radiotherapy boost for gynecological cancer when brachytherapy is not an option. European Journal of Gynaecological Oncology. 2020. 41(5);720-725.

References

[1] Al Feghali K.A., Elshaikh M.A.: “Why brachytherapy boost is the treatment of choice for most women with locally advanced cervical carcinoma?”. Brachytherapy, 2016, 15, 191-199.

[2] Scholten A.N., Van Putten W.L., Beerman H., Smit V.T., Koper P. C., Lybeert M.L., et al.: “Postoperative radiotherapy for stage I endometrial carcinoma. Long-term outcome of the randomized PORTEC trial with central pathology review”. Int J Radiat Oncol Biol Phys, 2005; 63: 834-838.

[3] Viswanathan A.N., Moughan J., Small W., Levenback C., Iyer R., Hymes S., et al.: “The Quality of Cervical Cancer Brachytherapy Implantation and the Impact on Local Recurrence and Disease-Free Survival in Radiation Therapy Oncology Group Prospective Trials 0116 and 0128”. International Journal of Gynecologic Cancer, 2012, 22, 123-131.

[4] Kirchheiner K., Nout R.A., Czajka-Pepl A., Ponocny-Seliger E., Sturdza A.E., Dimopoulos J.C., et al.: “Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery — A mono-institutional prospective study”. Gynecol. Oncol., 2015, 136, 415-423.

[5] Nout R.A., Smit V.T.H.B., Putter H., Jürgenliemk-Schulz I.M., Jobsen J.J., Lutgens L.C., et al.: “Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial car-cinoma of high-intermediate risk (PORTEC 2): An open-label, non-inferiority, randomized trial”. Lancet, 2010; 375, 816-823.

[6] Kavanagh B.D., Schefter T.E., Wu Q., Tong S., Newman F., Arnfield M., et al.: “Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer”. Semin. Radiat. Oncol., 2002, 12, 260-271.

[7] Schefter T.E., Kavanagh B.D., Wu Q., Tong S., Newman F., Mc-court S., et al.: “Technical considerations in the application of intensity-modulated radiotherapy as a concomitant integrated boost for locally-advanced cervix cancer”. Med. Dosim., 2002, 27, 177-184.

[8] Low D.A., Grigsby P.W., Dempsey J.F., Mutic S., Williamson J.F., Markman J., et al.: “Applicator-guided intensity-modulated radio-therapy”. Int J Radiat Oncol Biol Phys, 2002, 52, 1400-1406.

[9] Guerrero M., Li X.A., Ma L., Linder J., Deyoung C., Erickson B.: “Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: Radiobiological and dosimetric considerations”. International Journal of Radiation Oncology*Biology*Physics, 2005, 62, 933-939.

[10] Mazzola R., Ricchetti F., Fiorentino A., Levra N.G., Fersino S., Di Paola G., et al.: “Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly Patients: Feasibility and Clinical Preliminary Results”. Technology in Cancer Research & Treatment, 2017, 16, 310-315.

[11] Viswanathan A.N., Beriwal S., De Los Santos J.F., Demanes D.J., Gaffney D., Hansen J., et al.: “American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy”. Brachytherapy, 2012, 11, 47- 52.

[12] Mahmoud O., Kilic S., Khan A.J., Beriwal S., Small W.J.: “Exter-nal beam techniques to boost cervical cancer when brachytherapy is not an option—theories and applications”. Annals of Translational Medicine, 2017, 5, 207-207.

[13] Haas J.A., Witten M.R., Clancey O., Episcopia K., Accordino D., Chalas E.: “CyberKnife Boost for Patients with Cervical Cancer Unable to Undergo Brachytherapy”. Frontiers in Oncology, 2012, 2,

[14] Marnitz S., Köhler C., Budach V., Neumann O., Kluge A., Wlodar-czyk W., et al.: “Brachytherapy-emulating robotic radiosurgery in patients with cervical carcinoma”. Radiat. Oncol., 2013, 8.

[15] Kubicek G.J., Xue J., Xu Q., Asbell S.O., Hughes L., Kramer N., et al.: “Stereotactic Body Radiotherapy as an Alternative to Brachytherapy in Gynecologic Cancer”. Biomed Research Interna-tional, 2013, 2013, 1-6.

[16] Kagei K., Tokuuye K., Okumura T., Ohara K., Shioyama Y., Sug-ahara S., et al.: “Long-term results of proton beam therapy for carcinoma of the uterine cervix”. International Journal of Radiation Oncology*Biology*Physics, 2003, 55, 1265-1271.

[17] Park H.C., Department of Radiation Oncology, Sungkyunkwan Uni-versity School of Medicine, Samsung Medical Center, Seoul, Korea., Shimizu S., Yonesaka A., Tsuchiya K., Ebina Y., et al.: “High Dose Three-Dimensional Conformal Boost Using the Real-Time Tumor Tracking Radiotherapy System in Cervical Cancer Patients Unable to Receive Intracavitary Brachytherapy”. Yonsei Med. J., 2010, 51, 93.

[18] Chan P., Yeo I., Perkins G., Fyles A., Milosevic M.: “Dosimetric comparison of intensity-modulated, conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: a retrospective planning study”. Radiat Oncol, 2006, 1, 13.

[19] Matsuura K., Tanimoto H., Fujita K., Hashimoto Y., Murakami Y., Kenjo M., et al.: “Early clinical outcomes of 3D-conformal radio-therapy using accelerated hyperfractionation without intracavitary brachytherapy for cervical cancer”. Gynecol. Oncol., 2007, 104, 11-14.

[20] Barraclough L.H., Swindell R., Livsey J.E., Hunter R.D., Davidson S. E.: “External Beam Boost for Cancer of the Cervix Uteri When Intracavitary Therapy Cannot Be Performed”. International Journal of Radiation Oncology*Biology*Physics, 2008, 71, 772-778.

[21] Hsieh C.H., Tien H.J., Hsiao S.M., Wei M.C., Wu W.Y., Sun H.D., et al.: “Stereotactic body radiation therapy via helical tomotherapy to replace brachytherapy for brachytherapy-unsuitable cervical cancer patients – a preliminary result”. Onco Targets Ther, 2013, 6, 59-66.

[22] Mantz C.A.: “Stereotactic Body Radiation Therapy as a Boost Alternative for Nonmetastatic Cancer of the Cervix and Endometrium: Disease Control and Quality of Life Outcomes From a Phase 2 Trial at 3 Years’ Minimum Follow-up”. International Journal of Radiation Oncology*Biology*Physics, 2016, 96, E286.

[23] Kemmerer E., Hernandez E., Ferriss J. S., Valakh V., Miyamoto C., Li S., et al.: “Use of Image-Guided Stereotactic Body Radiation Therapy in Lieu of Intracavitary Brachytherapy for the Treatment of Inoperable Endometrial Neoplasia”. International Journal of Radiation Oncology*Biology*Physics, 2013, 85, 129-135.

[24] Wulf J., Hädinger U., Oppitz U., Thiele W., Flentje M.: “Stereotactic boost irradiation for targets in the abdomen and pelvis”. Radiother. Oncol., 2004, 70, 31-36.

[25] Demiral S., Beyzadeoglu M., Uysal B., Oysul K., Kahya Y. E., Sager O., et al.: “Evaluation of stereotactic body radiotherapy (sbrt) boost in the management of endometrial cancer”. Neoplasma, 2013, 60, 322- 327.

[26] Kucera H., Knocke T.H., Kucera E., Potter R.: “Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients”. Acta Obstet. Gynecol. Scand., 1998, 77, 1008-1012.

[27] Wahab S.H., Malyapa R.S., Mutic S., Grigsby P.W., Deasy J.O., Miller T.R., et al.: “A treatment planning study comparing HDR and AGIMRT for cervical cancer”. Med. Phys., 2004, 31, 734-743.

[28] Gielda B.T., Shah A.P., Marsh J.C., Smart J.P., Bernard D., Rot-mensch J., et al.: “Helical tomotherapy delivery of an IMRT boost in lieu of interstitial brachytherapy in the setting of gynecologic malignancy: feasibilty and dosimetric comparison”. Med Dosim, 2011, 36, 206-212.

[29] Cengiz M., Dogan A., Ozyigit G., Erturk E., Yildiz F., Selek U., et al.: “Comparison of intracavitary brachytherapy and stereotactic body radiotherapy dose distribution for cervical cancer”. Brachytherapy, 2012, 11, 125-129.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top